Independent validation of a pre-specified four-kallikrein marker model for prediction of adverse pathology and biochemical recurrence

• DOI: 10.1038/s41416-021-01661-x
• Publication Date: 2021-12-13T17:47:34Z
• Authors: Martin Rasmussen; Jacob Fredsøe; Amy L. Tin; Andrew J. Vickers; Benedicte Ulhøi; Michael Borre; James Eastham; Behfar Ehdaie; Bertrand Guillonneau; Vincent Laudone; Peter T. Scardino; Karim Touijer; Karina D. Sørensen; Hans Lilja
• Keywords: Male; Prostatectomy; OUTCOMES; Prostate/pathology; RADICAL PROSTATECTOMY; Prostate; Prostatic Neoplasms; PROGRESSION; Prostatic Neoplasms/pathology; Prostate-Specific Antigen; CANCER; DISEASE; ACTIVE SURVEILLANCE; 3. Good health; PROSTATE-SPECIFIC ANTIGEN; 03 medical and health sciences; 0302 clinical medicine; BIOPSY; INTACT; KALLIKREIN 2; Humans; Kallikreins; Neoplasm Grading

Accurate markers for prostate cancer (PC) risk stratification could aid decision-making for initial management strategies. The 4Kscore has an undefined role in predicting outcomes after radical prostatectomy (RP).We included 1476 patients with 4Kscore measured prior to RP at two institutions. The 4Kscore was assessed for prediction of adverse pathology at RP and biochemical recurrence (BCR) relative to a clinical model. We pre-specified that all analyses would be assessed in biopsy Grade Group 1 (GG1) or 2 (GG2) PC patients, separately.The 4Kscore increased discrimination for adverse pathology in all patients (delta area under the receiver operative curve (AUC) 0.009, 95% confidence interval (CI) 0.002, 0.016; clinical model AUC 0.767), driven by GG1 (delta AUC 0.040, 95% CI 0.006, 0.073) rather than GG2 patients (delta AUC 0.005, 95% CI -0.012, 0.021). Adding 4Kscore improved prediction of BCR in all patients (delta C-index 0.014, 95% CI 0.007, 0.021; preop-BCR nomogram C-index 0.738), again with larger changes in GG1 than in GG2.This study validates prior investigations on the use of 4Kscore in men with biopsy-confirmed PC. Men with GG1 PC and a high 4Kscore may benefit from additional testing to guide treatment selection. Further research is warranted regarding the value of the 4Kscore in men with biopsy GG2 PC.